Is there a role for cyclosporine in asthma?

European Journal of Pharmacology, 2001

The immunosuppressant cyclosporin A given orally has anti-asthma properties but carries an undesirable risk of systemic effects. We Ž .

The Journal of Immunology, 2010

Supplementary 7.DC1 http://www.jimmunol.org/content/suppl/2010/11/05/jimmunol.100170 References http://www.jimmunol.org/content/185/12/7663.full#ref-list-1 , 18 of which you can access for free at: cites 40 articles This article Subscription http://jimmunol.org/subscription is online at: The Journal of Immunology Information about subscribing to

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2017

The aim of this study is to show if cyclosporine has an antiallergic role in a rat model of ovalbumin-induced allergic rhinitis. The 54 rats were divided into six equal groups. The first group was a negative control group without induced allergic rhinitis; the second group a positive control with induced allergic rhinitis not receiving treatment. The remaining four groups, after induction of allergic rhinitis, received intranasal cyclosporine treatment in doses of 0.05, 0.1, or 0.2% or nasal steroid treatment. In the biochemical examination, on the surface of the tissue tumor necrosis factor (TNF) interferon (IFN), interleukin (IL)-5, IL-13, as well as IL-2, IL-4, IL-17A, and IgE were studied. Histologically, ciliary loss, increase of goblet cells, vascular congestion, and the degree of eosinophil infiltration were rated. In all treatment groups, on average, a significant reduction in all histological and biochemical values was found compared to the positive control group. Comparing...

Journal of Allergy and Clinical Immunology, 1971

Eleven asthmatio men were treated with the antimetabolites thioguanosine or 6-meroaptopurine. Eight completed IS weeTcs of treatment. Beversiile drug toxidty occurred in $ patients. Four patients with severe chronic asthma, chronic bronchitis, and contirmous wheezing were not improved. Five patients with intermittent asthma of recent onset improved and had no severe attacks during therapy. Two of them showed consistently improved air flow rates and hlood oxygenation, though some obstruction to air flow persisted. The cytology and types of mucus in stained sections of sputum helped to classify patients. Immunosuppressive therapy may prove to he useful in selected patients who have asthma but do not have chronic bronchitis.

American Journal of Health-System Pharmacy, 1984

CP Digest is a monthly section that provides summaries of articles from Clinical Pharmacy, ASHP's journal of current concepts in drug therapy for pharmacists. One issue of the bi monthly Clinical Pharmacy is covered over two installtnents of this section. Major revieio articles are treated xoith lengthy digests that convey the key information from the articles. Abstracts of Re search papers are reprinted as they appear in CP and Research Notes and Drug Experience reports are covered briefly. An ad dress for reprints of the complete article is provided. CP sections such as Neios, Letters, Therapy Consultation, Editorials, and Current Literature are not covered in CP Digest.

Pediatric Asthma, Allergy & Immunology, 1996

Background: The pathogenesis of asthma involves hyperreactivity and chronic inflammation of airways in which CD4+ T cells play a major role. In atopic asthmatics, Thl responses due to interferon-gamma (IFN-y) are depressed, and Th2 responses due to interleukins (IL-4, IL-10) are predominant. It is not clear if cytokine secretion patterns change with clinical improvement during immunotherapy. Objectives: Monitoring IFN-y and IL-10 may be very useful in evaluating the effectiveness and response to allergen immunotherapy and in developing new therapeutic interventions with specific cytokine antagonists or peptides. Materials and Methods: Peripheral blood mononuclear cells were obtained from healthy nonasthmatic controls (N = 5) and from atopic asthmatic patients (N = 5) prior to immunotherapy and at 3 and 6 months after initiation of immunotherapy to monitor cytokine secretion (IFN-y, IL-10) in unstimulated and grass and ragweed allergen-specific stimulated mononuclear cells. Changes in cytokine secretions were related to clinical response to immunotherapy. Results: Controls had significantly higher mean IFN-y secretion compared to asthmatics (P < 0.01). Mean IL-10 secretion was lower in controls than in asthmatics, but significant levels were noted only with grass allergen (P < 0.03). In asthmatics, 3 months after starting immunotherapy mean IFN-y secretion significantly increased (P < 0.01) in both stimulated and unstimulated cells, which persisted at 6 months. Although there was no significant change in IL-10 secretion at 3 months, mean IL-10 secretion at 6 months was significantly decreased in allergen-stimulated cells (P < 0.02). Conclusion: In atopic asthmatics, mean IFN-y secretion significantly increased and allergen-specific IL-10 secretion was significantly decreased during immunotherapy.

Journal of the European Academy of Dermatology and Venereology, 1994

In order to evaluate the effect of Cyclosporin-A (CyA) at doses of 5 mg/kg per day in atopic dermatitis we studied clinical effects, immunoglobulin production, lymphocytes subset, immunphenotype and local cytokine production in seven patients before and after 3 months CyA therapy. Clinically CyA was very effective in eliminating pruritus, erythema and vescicles with no significant adverse side effects. Using flow cytometric analysis we demonstrated that CyA treatment restored an overcxpression of circulating CD25-positive cells. Similar results have been recorded with HLA-DR expression. CyA normalized the number of CD29 cells which were reduced in the blood of patients before starting treatment. Furthermore, after treatment, several eytokines (IL-2, IL-la and IL-l^) had diasappeared from the epidermis.

Clinical and Experimental Dermatology, 1989

There are theoretical reasons to anticipate a beneficial action of cyclosporin in atopic dermatitis. We describe a patient with severe atopic dematitis who responded dramatically while receiving cyclosporin for the treatment of lymphoma. Cyclosporin may have a useful role in patients with resistant atopic dermatitis.

Journal of Allergy and Clinical Immunology, 2001

We have used an optimized, physiologically relevant in vitro assay system to show that in a concentration-dependent fashion the immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin), as well as the glucocorticoid dexamethasone, inhibit allergen-driven T-cell proliferation and IL-5 production in PBMCs from allergensensitized atopic asthmatic individuals at physiologic concentrations. This effect of cyclosporin A might at least partially account for its established clinical efficacy in sparing systemic glucocorticoid therapy while improving lung function in chronic, severe, glucocorticoid-dependent asthma. The data are also compatible with the hypothesis that the newer immunomodulatory drugs mycophenolate mofetil and sirolimus exert similar effects, perhaps with a more favorable benefit/risk ratio. (J Allergy Clin Immunol 2001;108:915-7.)

Asthma is a chronic inflammatory disease of the airways characterized by fibrosis of the airways, hyperplasia and hypertrophy of smooth muscle cells and mucous secreting cells due to infiltration of activated eosinophils and activation of resident mast cells and lymphocytes. These chronic inflammatory changes are mediated by secretion of cytokines from inflammatory cells. Cytokines play integral role in the coordination and persistence of inflammatory process in chronic inflammation of the airways. Based on the recent understanding of pathogenesis of asthma, cytokines are classified as a) Lymphokines, b) Proinflammatory cytokines, c) Antiinflammatory cytokines and d) Chemokines. The biology of cytokines seem to be complex and may not confine to inflammatory reactions as some of them do possess anti-inflammatory properties. Current therapies for asthma provide only symptomatic relief to patients and do not control inflammation. Modern treatment of asthma is directed towards lessening...